Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: The intergroup trial JCOG0803/WJOG4307L

Journal of Clinical Oncology

Volumn 33, Issue 6, 2015, Pages 575-581

  Abe, Tetsuya ^a   Takeda, Koji ^b   Ohe, Yuichiro ^f   Kudoh, Shinzoh ^c   Ichinose, Yukito ^g   Okamoto, Hiroaki ^h   Yamamoto, Nobuyuki ⁱ   Yoshioka, Hiroshige ^j   Minato, Koichi ^k   Sawa, Toshiyuki ^l   Iwamoto, Yasuo ^m   Saka, Hideo ⁿ   Mizusawa, Junki ^p   Shibata, Taro ^p   Nakamura, Shinichiro ^d   Ando, Masahiko ^o   Yokoyama, Akira ^a   Nakagawa, Kazuhiko ^e   Saijo, Nagahiro ^q   Tamura, Tomohide ^r  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c Osaka Prefecture University   (Japan)

^d West Japan Oncology Group Data Center   (Japan)

^e KINKI UNIVERSITY   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

ⁱ WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^j KURASHIKI CENTRAL HOSPITAL   (Japan)

^k Gunma Cancer Center   (Japan)

^l Gifu Municipal Hospital   (Japan)

^m HIROSHIMA CITY HOSPITAL   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^o NAGOYA UNIVERSITY HOSPITAL   (Japan)

^p NATIONAL CANCER CENTER   (Japan)

^q Japanese Society of Medical Oncology   (Japan)

^r NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; TAXOID;

ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DETERIORATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENE MUTATION; GERIATRIC PATIENT; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGE; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; MULTICENTER STUDY; PATHOLOGY; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; QUALITY OF LIFE; TAXOIDS;

EID: 84923126063     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.8627     Document Type: Article

References (23)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. National Cancer Institute: SEER Stat fact sheets: Lung and bronchus. http://seer.cancer.gov/statfacts/html/lungb.html
3. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
4. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003
5. Kudoh S, Takeda K, Nakagawa K, et al: Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24: 3657-3663, 2006
6. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266, 2009
7. Azzoli CG, Temin S, Giaccone G: 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 8:63-66, 2012
8. Reck M, Popat S, Reinmuth N, et al: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii27-iii39, 2014 (suppl 3)
9. Belani CP, Fossella F: Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 104: 2766-2774, 2005
10. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002
11. Lichtman SM, Wildiers H, Launay-Vacher V, et al: International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14-34, 2007
12. Ohe Y, Niho S, Kakinuma R, et al: Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. Jpn J Clin Oncol 31:100-106, 2001
13. Ohe Y, Niho S, Kakinuma R, et al: A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 15:45-50, 2004
14. Tsukada H, Yokoyama A, Goto K, et al: Randomized controlled trial comparing docetaxelcisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207. Jpn J Clin Oncol [epub ahead of print on November 6, 2014]
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
17. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
18. Quoix E, Zalcman G, Oster JP, et al: Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378:1079-1088, 2011
19. Yoshida K, Yatabe Y, Park J, et al: Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. J Cancer Res Clin Oncol 136:527-535, 2010
20. Wu M, Zhao J, Song SW, et al: EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 67:343-347, 2010
21. Chen YM, Shih JF, Perng RP, et al: A randomized trial of different docetaxel schedules in nonsmall cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 129:1031-1038, 2006
22. Esteban E, González de Sande L, Fernández Y, et al: Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 14:1640-1647, 2003
23. Tamiya A, Tamiya M, Shiroyama T, et al: Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Ann Oncol 24:980-985, 2013